TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis in people with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome. The agency says it is the first FDA-approved treatment for symptoms of the rare genetic condition; studies found reduced excess thyroid hormone levels and improvements in some cardiovascular and metabolic measures.
The U.S. Food and Drug Administration on September 28, 2026, approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The FDA describes it as the first approved therapy for symptoms of the rare genetic disease, which can leave patients with too little thyroid hormone reaching the brain while excess hormone circulates in the blood.
The FDA said Emcitate’s active ingredient, tiratricol, can enter cells without relying on the MCT8 transporter, the protein that does not function properly in the condition. The treatment is intended to reduce elevated thyroid hormone levels in the bloodstream and address peripheral thyrotoxicosis, which can cause symptoms including rapid heart rate, increased blood pressure and effects on metabolism. The approval is for that condition in people with MCT8 deficiency; the FDA release does not say the drug repairs the underlying genetic fault.
The agency evaluated effectiveness in two clinical studies involving patients from infancy through adulthood: an international, multicenter randomized, placebo-controlled trial and a longer-term open-label study. Across the studies, the FDA reported lower excess thyroid hormone levels among patients treated with Emcitate, along with improvements in cardiovascular and metabolic symptoms affected by thyroid levels, including systolic blood pressure and heart rate. The release does not provide numerical effect sizes or describe how large or consistent those changes were for individual patients.
Emcitate is taken once daily as a liquid suspension, by mouth or through a feeding tube for patients who have difficulty swallowing. The FDA listed diarrhea, vomiting, rash and excessive sweating as the most common side effects. It also warned that patients taking another thyroid medication should speak with their health care provider before starting Emcitate because the two medicines should not be used together. The FDA granted the approval to Egetis Therapeutics US Inc.
A New Option for Thyroid Imbalance
The approval adds a FDA-authorized treatment for excess thyroid hormone in the blood in a condition for which the agency says there had been no approved treatment option. MCT8 deficiency can affect movement, speech, intellectual development, feeding, the heart and metabolism, according to the FDA. The agency’s description of Emcitate’s action addresses one part of the disorder: the abnormal circulation of thyroid hormone when the transporter needed for its movement into the brain is faulty.
The study findings reported by the FDA are relevant to families and clinicians managing cardiovascular and metabolic effects, but they should not be read as evidence that the treatment reverses every effect of the disease. The release reports changes in hormone levels and certain symptoms; it does not claim that Emcitate restores thyroid hormone delivery to the brain or resolves neurological and developmental effects. Its once-daily liquid form, including use through a feeding tube, is designed to accommodate patients who cannot swallow tablets normally.
As an affiliate, we earn on qualifying purchases.
How MCT8 Deficiency Disrupts Hormone Transport
MCT8 deficiency is a rare genetic disorder that primarily affects males, the FDA said. It is caused by a faulty gene that provides instructions for making the MCT8 transporter, a protein involved in moving thyroid hormone into the brain. In the agency’s account, without a functioning transporter, the brain receives too little of the hormone while elevated levels build up in the bloodstream.
The FDA says affected people may have substantial disabilities, including inability to sit or walk independently, absent or severely limited speech, intellectual disability and feeding difficulties, as well as chronic stress on the heart and metabolism. Tiratricol’s proposed relevance is that it can enter cells without relying on the impaired transporter, according to the FDA. Before this approval, the agency said, patients and families had no FDA-approved treatment option for the condition’s symptoms.
The drug received Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations, as well as Priority Review, the FDA said. Those designations and review status describe regulatory programs and review processes; the agency’s announcement does not present them as separate evidence of clinical benefit.
“This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.”
— Hylton V. Joffe, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology at the FDA’s Center for Drug Evaluation and Research
thyroid hormone medication for MCT8 deficiency
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Evidence Reported
The FDA’s announcement reports that hormone levels fell and some cardiovascular and metabolic measures improved, but it does not give numerical results, the size of the changes, or details about how long benefits lasted. It also does not specify how outcomes varied by age, disease severity or individual patient. The agency describes one randomized placebo-controlled study and one longer-term open-label study, but the release does not provide their full results or explain the extent of follow-up.
It remains unclear from the announcement whether treatment changes neurological, developmental, mobility, speech or feeding outcomes, or affects the long-term course of MCT8 deficiency. The FDA’s stated indication concerns peripheral thyrotoxicosis, and the release does not describe Emcitate as a cure or as a way to restore normal hormone transport into the brain. Further information on longer-term effectiveness and safety is not included in the release.
peripheral thyrotoxicosis treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Treatment Use and Follow-Up
Emcitate is now FDA-approved for its stated use, and patients and caregivers can discuss whether it is appropriate with their treating health care professionals. The FDA specifically advises people taking another thyroid medication to consult a provider before starting the drug, because the medicines should not be used together. Clinicians and families will also need to monitor for the side effects listed by the agency, including diarrhea, vomiting, rash and excessive sweating.
The approval was granted to Egetis Therapeutics US Inc. The FDA announcement does not provide a launch date, price, prescribing details or information about access and insurance coverage. Those practical details, along with additional data on longer-term outcomes, remain outside the information provided in the release.
liquid thyroid medication for children
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis, or excess thyroid hormone in the blood, in patients with MCT8 deficiency.
Is Emcitate a cure for MCT8 deficiency?
The FDA approved it to treat peripheral thyrotoxicosis associated with the condition. The agency’s announcement does not describe it as a cure or say that it corrects the genetic fault or restores normal thyroid hormone delivery to the brain.
How is Emcitate taken?
It is taken once daily as a liquid suspension, either by mouth or through a feeding tube, according to the FDA.
What side effects did the FDA report?
The most common side effects listed in the FDA release were diarrhea, vomiting, rash and excessive sweating. The agency also says patients using another thyroid medication should talk to their health care provider before starting Emcitate because the drugs should not be used together.
What benefits were reported in the studies?
Across two studies, the FDA reported reductions in excess blood thyroid hormone and improvements in some cardiovascular and metabolic symptoms, including systolic blood pressure and heart rate. The announcement does not provide numerical effect sizes or report whether neurological or developmental outcomes changed.
Source: primary
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
